Clinical Trials · NCT06937749
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Enrollment
- 165
- Start date
- Jul 2025
- Locations
- 1 site, China
- Primary endpoint
- Percentage of Participants With MASH resolution With no Worsening of Fibrosis on Liver Histology